Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) announced a private placement priced at-the-market to raise approximately $5.0 million upfront and up to $8.9 million additional if warrants are fully exercised. The offering includes 2,222,223 shares and Series I and J warrants exercisable at $2.00.
Closing expected on or about April 17, 2026; H.C. Wainwright is placement agent. Net proceeds to fund product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced that U.S. Patent No. 12,577,232 was issued on March 17, 2026, covering its EVM301 Series of N-heterocycle substituted tryptamine derivatives.
The patent claims chemical compounds, pharmaceutical formulations, and methods for treating brain neurological disorders and expands coverage alongside U.S. Patent No. 12,338,231. Enveric cites lead candidate EB-003 and says it is progressing toward an IND submission and a first-in-human Phase 1 trial. The company reports a patent estate of 27 issued U.S. patents and approximately 60 pending national and international applications.
Enveric Biosciences (NASDAQ: ENVB) reported fourth-quarter and year‑end 2025 results and operational updates on March 27, 2026. Key points: positive preclinical data for EB-003 in models of severe chronic depression and PTSD, FDA feedback allowing a streamlined IND plan, multiple patent issuances and a withdrawn PGR petition, manufacturing CMC milestones, a 1-for-12 reverse stock split, and $4.7M cash on hand at year‑end.
The company raised $12.2M in fiscal 2025 (including $4.9M in Q4) and reported a Q4 net loss attributable to stockholders of $4.0M (loss per share $6.12).
Enveric Biosciences (NASDAQ: ENVB) announced that the Canadian Intellectual Property Office registered five trademarks, including house marks Enveric and Enveric Biosciences.
The registrations also cover two Plus Marks for product packaging and the trademark "Next Generation Mental Health". The company said it plans an IND filing for lead molecule EB-003 with the FDA in 2026.
Enveric Biosciences (NASDAQ: ENVB) announced that the Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against U.S. Patent No. 12,138,276 has been withdrawn and the PTAB granted the withdrawal, leaving no remaining challenges to the '276 patent.
The '276 patent covers halogenated psilocybin derivatives with claims relevant to bretisilocin (GM-2505), and the filing timeline cites events from August–November 2025 including AbbVie's up-to-$1.2 billion acquisition of bretisilocin from Gilgamesh.
Enveric Biosciences (NASDAQ: ENVB) reported proprietary BRET assay data showing its lead candidate EB-003 engages both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor. The company said EB-003 shows a modest β-arrestin bias versus serotonin and that both pathways are engaged at biologically relevant levels. Enveric plans additional BRET testing including the Gi pathway and continues to advance EB-003 through IND-enabling studies.
Enveric Biosciences (NASDAQ: ENVB) announced that subsidiary Akos Biosciences licensed its US RCANN™ trademark portfolio and an RCANN design to TOTEC Pharma, an Aries affiliate, to support commercialization of a patented cannabinoid crème intended for radiation dermatitis.
The license includes an option to purchase the trademark portfolio if TOTEC meets specified development and commercialization milestones, and Enveric said the deal could lead to future milestone payments and royalties tied to product success.
Enveric Biosciences (NASDAQ: ENVB) announced on January 28, 2026 the closing of a registered direct offering of 328,802 common shares at $4.41 per share, generating approximately $1.5 million in gross proceeds. Concurrent private placements issued series G and H warrants to purchase up to 328,802 shares each.
The series G warrants have a $4.16 exercise price, are exercisable immediately and expire five years after the registration effective date; series H warrants have a $4.16 exercise price, are exercisable immediately and expire eighteen months after the registration effective date. Proceeds are intended for product development, working capital and general corporate purposes.
Enveric (NASDAQ: ENVB) announced a registered direct offering of 328,802 shares at $4.41 per share and concurrent private placement of two warrant series covering up to 328,802 shares each.
Gross proceeds are expected to be approximately $1.5 million before fees; series G and H warrants have $4.16 exercise prices and differing expiry terms.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of U.S. Patent No. 12,492,179 on December 29, 2025, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The patent claims compositions and treatment methods for novel, potentially neuroplastogenic and non‑hallucinogenic molecules, expands the company’s pipeline of patent‑protected candidates, and provides composition‑of‑matter protection intended to strengthen licensing and partnership prospects in neuropsychiatric, neurological, and addiction disorders.